Komori
Share Issuance and Disposal4596Kubota Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Notice Concerning the Bulk Exercise of the 41st Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued Through a Third-Party Allotment

From 10 November 2026 to 20 November 2026, 20,200 of the 41st Stock Acquisition Rights were exercised, and 2,020,000 new shares were issued. The unexercised balance was 179,800 rights (17,980,000 shares).

Worth reading
70In focus
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
2020000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Exercise status of the 41st Stock Acquisition Rights (with Exercise Price Adjustment Clause) issued through a third-party allotment

Who receives how much2,020,000Shares

2,020,000 shares (new shares)

EVO FUND (the allottee at the time the 41st Stock Acquisition Rights were issued)

The lower thin line represents the existing number of shares to which these shares will be added.

Existing Shares and Increase
+1.25%Rate of increase
162,144,288 shares164,164,288Shares

Approximately 1.25% (2,020,000 shares ÷ 162,144,288 shares outstanding as of 9 November 2026)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
The exercise price during the exercise period was ¥48, ¥51, ¥53, ¥55 and ¥60 on the respective days. Details of the adjustment clause and the floor: Not disclosed
Number of Stock Acquisition Rights
Total issued: 200,000 rights; unexercised balance as of 9 November 2026: 200,000 rights; current unexercised balance: 179,800 rights
Most recent equity financing
Timing 9 November 2026 / Type Issuance of the 41st Stock Acquisition Rights (with Exercise Price Adjustment Clause) through a third-party allotment / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalExercise status of the 41st Stock Acquisition Rights (with Exercise Price Adjustment Clause) issued through a third-party allotment
Number of shares to be issued or disposed of2,020,000 shares (new shares)
Intended allotteeEVO FUND (the allottee at the time the 41st Stock Acquisition Rights were issued)
Dilution RateApproximately 1.25% (2,020,000 shares ÷ 162,144,288 shares outstanding as of 9 November 2026)
Total number of issued shares162,144,288 shares (as of 9 November 2026) → 164,164,288 shares (if the shares exercised this time are reflected)(Approximately 1.25%)
Exercise priceThe exercise price during the exercise period was ¥48, ¥51, ¥53, ¥55 and ¥60 on the respective days. Details of the adjustment clause and the floor: Not disclosed
Number of Stock Acquisition RightsTotal issued: 200,000 rights; unexercised balance as of 9 November 2026: 200,000 rights; current unexercised balance: 179,800 rights
Most recent equity financingTiming 9 November 2026 / Type Issuance of the 41st Stock Acquisition Rights (with Exercise Price Adjustment Clause) through a third-party allotment / Amount Not disclosed
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the status of the substantial exercise.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Bulk Exercise of the 41st Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued Through a Third-Party Allotment | Kubota Pharmaceutical Holdings Co.,Ltd. (4596) timely disclosure | Komori